Prevalence and risk factors of prolonged QTc interval in HIV-infected patients: Results of the HIV-HEART study

HIV Clinical Trials

Volumn 10, Issue 4, 2009, Pages 261-268

  Reinsch, Nico ^a   Buhr, Christiane ^a   Krings, Peter ^a   Kaelsch, Hagen ^a   Neuhaus, Kathrin ^a   Wieneke, Heiner ^a   Erbel, Raimund ^a   Neumann, Till ^a  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

Electrocardiogram; HIV; Long QT; QTc prolongation

Indexed keywords

PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ARTICLE; CARDIOVASCULAR RISK; COHORT ANALYSIS; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; GENDER; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PARAMETER; PREVALENCE; PRIORITY JOURNAL; QT INTERVAL; QT PROLONGATION; RISK ASSESSMENT;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; CROSS-SECTIONAL STUDIES; ELECTROCARDIOGRAPHY; FEMALE; HIV; HIV INFECTIONS; HUMANS; LONG QT SYNDROME; MALE; MIDDLE AGED; PREVALENCE;

EID: 70349116895     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/hct1004-261     Document Type: Article

References (37)

1. Tan HL, Hou CJ, Lauer MR, et al. Electrophysiologic mechanisms of the long QT interval syndromes and torsade de pointes. Ann Intern Med. 1995;122:701-714.
2. Haverkamp W, Hordt M, Chen X, et al. Torsade de pointes. Z Kardiol. 1993;82:763-774.
3. Schwartz PJ, Wolf S. QT interval prolongation as predictor of sudden death in patients with myocardial infarction. Circulation. 1978;57:1074-1077.
4. Kocheril AG, Bokhari SA, Batsford WP, et al. Long QTc and torsades de pointes in human immunodefi ciency virus disease. Pacing Clin Electrophysiol. 1997;20:2810-2816.
5. Anson BD, Weaver JG, Ackerman MJ, et al. Blockade of HERG channels by HIV protease inhibitors. Lancet. 2005;365:682-686.
6. Sani MU, Okeahialam BN. QTc interval prolongation in patients with HIV and AIDS. J Natl Med Assoc. 2005;97:1657-1661.
7. Strauss SM, Sturkenboom MC, Bleumink GS, et al. Noncardiac QTc-prolonging drugs and the risk of sudden cardiac death. Eur Heart J. 2005;26:2007-2012.
8. Neumann T, Esser S, Potthoff A, et al. HIV-HEART Study Investigative Group. Prevalence and natural history of heart failure in outpatient HIV-infected subjects: rationale and design of the HIV-HEART study. Eur J Med Res. 2007;12:243-248.
9. 1999 World Health Organization-International Society of Hypertension. Guidelines for the management of hypertension. Guidelines subcommittee. J Hypertens. 1999;17:151-183.
10. 12SL ECG analysis with age and gender specifi c criteria. Physician s guide. PN 416791004 Revision A. Freiburg: GE Medical Systems IT; 2000.
11. Willems JL, Abreu-Lima C, Arnaud P, et al. The diagnostic performance of computer programs for the interpretation of electrocardiograms. N Engl J Med. 1991;325:1767-1773.
12. Froelicher VF, Marcus R, Heidenreich PA. Prognostic value of computer electrocardiography in veteran outpatients. Fed Pract. 2004;3:11-20.
13. Robbins J, Nelson JC, Rautaharju PM, et al. Association between the length of the QT interval and mortality in the Cardiovascular Health Study. Am J Med. 2003;115:689-694.
14. Moss AJ. Measurement of the QT interval and the risk associated with QTC in interval prolongation: a review. Am J Cardiol. 1993;72:23-25.
15. Rothman KJ. Modern Epidemiology. Boston, MA: Little, Brown © Company; 1986.
16. Nordin C, Kohli A, Beca S, et al. Importance of hepatitis coinfection in the development of QT prolongation in HIVinfected patients. J Electrocardiol. 2006;39:199-205.
17. Villa A, Foresti V, Confalonieri F. Autonomic neuropathy and prolongation of QT interval in human immunodeficiency virus infection. Clin Auton Res. 1995;5:48-52.
18. Silvieri R, Veglio M, Chinaglia A, et al. Prevalence of QT prolongation in a type 1 diabetic population and its association with autonomic neuropathy. Diabet Med. 1993;10:920-924.
19. Lehmann MH, Hardy S, Archibald D, et al. Sex difference in risk of torsade de pointes with DL-sotalol. Circulation. 1996;94:2535-2541.
20. Wolbrette DL. Gender differences in the proarrhythmic potential of QT-prolonging drugs. Curr Womens Health Rep. 2002;2:105-159.
21. Drici MD, Clement N. Is gender a risk factor for adverse drug reactions? The example of drug-induced long QT syndrome. Drug Saf. 2001;24:575-585.
22. Busti AJ, Tsikouris JP, Peeters MJ, et al. A prospective evaluation of the effect of atazanavir on the QTc interval and QTc dispersion in HIV-positive patients. HIV Med. 2006;7:317-322.
23. Gianotti N, Guffanti M, Galli L, et al. Electrocardiographic changes in HIV-infected, drug-experienced patients being treated with atazanavir. AIDS. 2007;31:1648-1651.
24. Jonker DM, Kenna LA, Leishman D, et al. A pharmacokinetic-pharmacodynamic model for the quantitative prediction of dofetilide clinical QT prolongation from human a-ethera-go-go-related inhibition data. Clin Pharmacol Ther. 2005;77:572-582.
25. Zhou S, Chan SY, Goh BC, et al. Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. Clin Pharmacokinet. 2005;44:279-304.
26. Owens RC, Nolin TD. Correspondence: reply to Chinello and Petrosillo. Clin Infect Dis. 2007;44:1389-1391.
27. Castillo R, Pedalino RP, El-Sherif N, et al. Efavirenzassociated QT prolongation and torsade de pointes arrhythmia. Ann Pharmacother. 2002;36:1006-1008.
28. Gil M, Sala M, Anguera I, et al. QT prolongation and torsades de pointes in patients infected with human immunodefi ciency virus and treated with methadone. Am J Cardiol. 2003;92:995-997.
29. Hrovatin E, Zardo F, Brieda M, et al. Long QT and torsade de pointes in a patient with acquired human immunodeficiency virus infection in multitherapy with drugs affecting cytochrome P450. Ital Heart J Suppl. 2004;5:735-740.
30. Falconer M, Molloy D, Ingerhaug J, et al. Methadone induced torsade de pointes in a patient receiving antiretroviral therapy. Ir Med J. 2007;100:631-632.
31. Pearson EC, Woosley RL. QT prolongation and torsades de pointes among methadone users: reports to the FDA spontaneous reporting system. Pharmacoepidemiol Drug Saf. 2005;14:747-753.
32. Sudano I, Spieker LE, Noll G, et al. Cardiovascular disease in HIV infection. Am Heart J. 2006;151:1147-1155.
33. Brouillette J, Grandy SA, Jolicoeur P, et al. Cardiac repolarization is prolonged in CD4C/HIV transgenic mice. J Mol Cell Cardiol. 2007;43:159-167.
34. Becker K, Gorlach I, Frieling T, et al. Characterization and natural course of cardiac autonomic nervous dysfunction in HIV-infected patients. AIDS. 1997;11:751-757
35. Mittal CM, Wig N, Mishra S, et al. Heart rate variability in human immunodeficiency virus-positive individuals. Int J Cardiol. 2004;94:1-6.
36. Fliers E, Sauerwein HP, Romijn JA, et al. HIV-associated adipose redistribution syndrome as a selective-autonomic neuropathy. Lancet. 2003;362:1758-1760.
37. Lichenstein K, Balasubramanyam A, Sekhar R, et al. HIV-associated adipose redistribution syndrome (HARS): definition, epidemiology and clinical impact. AIDS Res Ther. 2007;4:16